Alvine Pharmaceuticals (San Carlos, CA) a clinical-stage biopharmaceutical company focused on autoimmune related GI disease such as Celiac disease, closed a $21.5M financing bringing the total round to $47.5M. Participants include Panorama Capital, InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.

aTyr Pharma (San Diego, CA) a preclinical-stage biopharmaceutical company focused on inflammation, autoimmune, hematopoietic and metabolic disorders, closed a $12M Series C financing. Participants include Alta Partners, Cardinal Partners and Polaris Ventures.

Avila Therapeutics (Waltham, MA) a preclinical-stage biopharmaceutical company focused on protein silencing drugs for viral infections, cancer and autoimmune diseases, closed a $30M Series B financing. Participants include Novartis Option Fund, Abingworth Management, Advent Venture Partners, Atlas Venture and Polaris Venture Partners.

Allostera Pharma (Canada) a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes, closed a $15.4M Series C financing. Participants include iNovia Capital, Genesys Capital, BDC Venture Capital and GO Capital.

Intellikine (La Jolla, CA) a preclinical-stage pharmaceutical company focused on oncology, inflammation and autoimmune diseases, closed a $51M Series B financing. Participants include Novartis Venture Funds, U.S. Venture Partners, Biogen Idec, FinTech Global Capital, Abingworth, CMEA Capital and Sofinnova Ventures.

Opsana Therapeutics (Ireland) a preclinical-stage small molecule company focused on autoimmune and inflammatory disease through toll-like receptor modulators closed a $4.6M Series B financing, bringing the total round to $27.5M. Participants include Roche Venture Fund, Enterprise Ireland, Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.

KeyNeurotek Pharmaceuticals (Germany) a clinical-stage small molecule company focused on autoimmune and CNS diseases, closed a $10.9M Series C financing. Participants include DVC Deutsche Venture Capital, IBG Beteiligungsgesellschaft and KfW Bankengruppe.

Opsana Therapeutics (Ireland) a preclinical-stage small molecule company focused on autoimmune and inflammatory disease through toll-like receptor modulators closed a $22.9M Series B financing. Participants include Novartis Venture Funds, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.

CalciMedica (La Jolla, CA) an early-stage company focused on the calcium release-activated calcium channel is pursuing autoimmune and inflammatory indications, closed a $4M Series C financing. Participants include Biogen Idec, Sanderling Ventures and SR One.

Proteolix (San Francisco, CA) developer of therapeutics targeting protein degradation pathways in cancer and autoimmune diseases, closed a $79M Series C financing. Participants include Nomura Phase4 Ventures, Westfield Capital Management, Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners, U.S. Venture Partners and The Vertical Group.

KaloBios Pharmaceuticals (San Francisco, CA) early-stage company focused on developing monoclonal therapeutics for inflammatory, autoimmune and infectious disease, closed a $20M Series D financing. Participants included Mitsubishi UFJ Capital, Genzyme Ventures, MPM Capital, Alloy Ventures, GBS Ventures, Sofinnova Ventures, Singapore Bioinnovations, Pte., 5AM Ventures and Lotus Bioscience Ventures.

SuppreMol (Germany) early-stage biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, closed a $25M Series B financing. Participants include MIG, BioMedInvest, Santo Holding, Zetacube, KfW Mittelstandsbank, Bayern Kapital and Max-Planck-Gesellschaft.

Peptimmune (Cambridge, MA) clinical-stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders, closed a $8.9M Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors and Silicon Valley Bank Capital.